| View |
|
DRP-11374-02
|
Cefoxitin (as sodium)
|
Cefoxy
|
1 g
|
Powder for Injection (IV)
|
Antibacterial (Cephalosporin)
|
Reyoung Pharmaceutical Co., Ltd.
|
China
|
CLIDP Conversion
|
27 September 2024
|
07 March 2027
|
| View |
|
DRP-11459-02
|
Gabapentin
|
Retapentin
|
300 mg
|
Capsule
|
Antiepileptic
|
Saga Lifesciences Limited
|
India
|
CLIDP Conversion
|
24 September 2024
|
15 March 2027
|
| View |
|
DRP-11525-03
|
Levofloxacin
|
Retafloxel
|
500 mg
|
Film-Coated Tablet
|
Antibacterial (Fluoroquinolone)
|
Ratnatris Pharmaceuticals Private Limited
|
India
|
CLIDP Conversion
|
08 October 2024
|
31 March 2027
|
| View |
|
DRP-11548-01
|
Cefuroxime (as sodium)
|
Zinafer
|
750 mg
|
Powder for Injection (IM/IV)
|
Antibacterial (Cephalosporin)
|
Medisure Laboratories Pakistan (Pvt.) Ltd.
|
Pakistan
|
CLIDP Conversion
|
28 September 2024
|
30 March 2027
|
| View |
|
DRP-11851-13
|
Montelukast (as sodium) + Levocetirizine Hydrochloride
|
Lelucazine
|
10 mg / 5 mg
|
Film-Coated Tablet
|
Leukotriene Receptor Antagonist / Antihistamine
|
Cooper Pharma Limited
|
India
|
CLIDP Conversion
|
27 September 2024
|
10 May 2027
|
| View |
|
DRP-11976-02
|
Salbutamol (as Sulfate)
|
Provexel NS
|
1 mg/mL (2.5 mg/2.5 mL)
|
Solution for Inhalation
|
Selective Beta-2-Adrenoreceptor Agonist
|
Eurolife Healthcare Pvt. Ltd
|
India
|
CLIDP Conversion
|
15 September 2024
|
27 December 2028
|
| View |
|
DRP-12061-01
|
Atenolol
|
Retanelol 50
|
50 mg
|
Tablet
|
Beta Blocking Agent
|
Acme Formulation Pvt. Ltd.
|
India
|
CLIDP Conversion
|
15 September 2024
|
06 June 2027
|
| View |
|
DRP-12062-01
|
Atenolol
|
Retanelol 100
|
100 mg
|
Tablet
|
Beta Blocking Agent
|
Acme Formulation Pvt. Ltd.
|
India
|
CLIDP Conversion
|
24 September 2024
|
06 June 2027
|
| View |
|
DRP-12592-05
|
Cefixime (as trihydrate)
|
Acecef
|
20 mg / mL
|
Powder for Oral Suspension (Oral Drops)
|
Antibacterial (Cephalosporin)
|
Globela Laboratories Private Limited
|
India
|
CLIDP Conversion
|
24 September 2024
|
19 September 2027
|
| View |
|
DRP-12623-06
|
Trimetazidine Hydrochloride
|
Tribest
|
35 mg
|
Modified-Release Tablet
|
Anti-Angina
|
Magbro Healthcare Pvt. Ltd
|
India
|
CLIDP Conversion
|
24 September 2024
|
29 November 2026
|
| View |
|
DRP-12678-01
|
Sevelamer carbonate
|
Sevecarbo
|
800 mg
|
Film-Coated tablet
|
Phosphate binder
|
Samson Laboratories Pvt. Ltd.
|
India
|
CLIDP Conversion
|
15 September 2024
|
22 September 2027
|
| View |
|
DRP-12683-02
|
Acetylcysteine
|
Acetylnium
|
600 mg
|
Powder for Oral Solution
|
Mucolytic
|
XL Laboratories Pvt. Ltd.
|
India
|
CLIDP Conversion
|
15 September 2024
|
22 September 2027
|
| View |
|
DRP-12691-02
|
Vildagliptin
|
None
|
50 mg
|
Tablet
|
Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
|
Lloyd Laboratories, Inc
|
Philippines
|
CLIDP Conversion
|
28 September 2024
|
22 September 2027
|
| View |
|
DRP-1272-14
|
Hydrocortisone (as sodium succinate)
|
Venecort 100
|
100 mg
|
Powder for Injection (IM/IV)
|
Corticosteroid
|
Umedica Laboratories Pvt. Ltd
|
India
|
CLIDP Conversion
|
28 September 2024
|
07 October 2028
|
| View |
|
DRP-12735-09
|
Telmisartan + Amlodipine (as besilate)
|
Retatel Plus 80/10
|
80 mg/10 mg
|
Tablet
|
Angiotensin II Receptor Blocker/ Calcium Channel Blocker
|
Evertogen Life Sciences Limited
|
India
|
CLIDP Conversion
|
24 September 2024
|
30 September 2027
|
| View |
|
DRP-12736-09
|
Telmisartan + Amlodipine (as besilate)
|
Retatel Plus 40/10
|
40 mg/10 mg
|
Tablet
|
Angiotensin II Receptor Blocker/ Calcium Channel Blocker
|
Evertogen Life Sciences Limited
|
India
|
CLIDP Conversion
|
27 September 2024
|
30 September 2027
|
| View |
|
DRP-12738-11
|
Telmisartan + Amlodipine (as besilate)
|
Retatel Plus 40/5
|
40 mg/5 mg
|
Tablet
|
Angiotensin II Receptor Blocker/ Calcium Channel Blocker
|
Evertogen Life Sciences Limited
|
India
|
CLIDP Conversion
|
15 September 2024
|
30 September 2027
|
| View |
|
DRP-12745-01
|
Sugammadex (as sodium)
|
Gadex-Star
|
100 mg / mL (200 mg/ 2 mL)
|
Solution for Injection (IV)
|
Antidote
|
USV Private Limited
|
India
|
CLIDP Conversion
|
24 September 2024
|
25 July 2027
|
| View |
|
DRP-12881-02
|
Sitagliptin (as phosphate) + Metformin Hydrochloride
|
Retaformin Plus
|
50 mg / 500 mg
|
Film-Coated Tablet
|
Antidiabetic Agent (Dipeptidyl peptidase 4 (DPP-4) inhibitor/Biguanide)
|
Eskayef Pharmaceuticals Limited
|
Bangladesh
|
CLIDP Conversion
|
27 September 2024
|
24 October 2027
|
| View |
|
DRP-12930-03
|
Co-Amoxiclav
|
Retavacyl 375
|
375 mg
|
Film-Coated Tablet
|
Antibacterial (Penicillin + Beta-Lactamase Inhibitor)
|
Yeluri Formulations Pvt Ltd.
|
India
|
CLIDP Conversion
|
24 September 2024
|
03 November 2027
|